167 related articles for article (PubMed ID: 22738414)
1. Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome.
Prince HM; Martin AG; Olsen EA; Fivenson DP; Duvic M
Leuk Lymphoma; 2013 Jan; 54(1):69-75. PubMed ID: 22738414
[TBL] [Abstract][Full Text] [Related]
2. A complete and durable response to denileukin diftitox in a patient with mycosis fungoides.
Carretero-Margolis CD; Fivenson DP
J Am Acad Dermatol; 2003 Feb; 48(2):275-6. PubMed ID: 12582402
[TBL] [Abstract][Full Text] [Related]
3. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
[TBL] [Abstract][Full Text] [Related]
4. Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Straus DJ
J Am Acad Dermatol; 2012 Nov; 67(5):867-75. PubMed ID: 22285675
[TBL] [Abstract][Full Text] [Related]
5. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies.
Duvic M; Geskin L; Prince HM
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):377-84. PubMed ID: 23770157
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
Talpur R; Duvic M
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma.
Duvic M; Martin AG; Olsen EA; Fivenson DP; Prince HM
Leuk Lymphoma; 2013 Mar; 54(3):514-9. PubMed ID: 22891708
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
Dang NH; Pro B; Hagemeister FB; Samaniego F; Jones D; Samuels BI; Rodriguez MA; Goy A; Romaguera JE; McLaughlin P; Tong AT; Turturro F; Walker PL; Fayad L
Br J Haematol; 2007 Feb; 136(3):439-47. PubMed ID: 17233846
[TBL] [Abstract][Full Text] [Related]
9. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
Chin KM; Foss FM
Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
[TBL] [Abstract][Full Text] [Related]
10. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
Dang NH; Hagemeister FB; Pro B; McLaughlin P; Romaguera JE; Jones D; Samuels B; Samaniego F; Younes A; Wang M; Goy A; Rodriguez MA; Walker PL; Arredondo Y; Tong AT; Fayad L
J Clin Oncol; 2004 Oct; 22(20):4095-102. PubMed ID: 15353540
[TBL] [Abstract][Full Text] [Related]
12. Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides.
Assaf C
Dermatol Clin; 2008 Jan; 26 Suppl 1():21-2. PubMed ID: 18405182
[No Abstract] [Full Text] [Related]
13. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
[TBL] [Abstract][Full Text] [Related]
14. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.
Foss FM; Borkowski TA; Gilliom M; Stetler-Stevenson M; Jaffe ES; Figg WD; Tompkins A; Bastian A; Nylen P; Woodworth T
Blood; 1994 Sep; 84(6):1765-74. PubMed ID: 8080984
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.
Frankel AE; Surendranathan A; Black JH; White A; Ganjoo K; Cripe LD
Cancer; 2006 May; 106(10):2158-64. PubMed ID: 16586495
[TBL] [Abstract][Full Text] [Related]
16. Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox.
Kazin R; Bujanauskas P; Vonderheid EC
J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S31-2. PubMed ID: 18191695
[No Abstract] [Full Text] [Related]
17. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.
Geskin LJ; Akilov OE; Kwon S; Schowalter M; Watkins S; Whiteside TL; Butterfield LH; Falo LD
Cancer Immunol Immunother; 2018 Mar; 67(3):423-434. PubMed ID: 29204699
[TBL] [Abstract][Full Text] [Related]
18. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
Talpur R; Duvic M
Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
[TBL] [Abstract][Full Text] [Related]
19. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides.
Ghori F; Polder KD; Pinter-Brown LC; Hoff AO; Gagel RF; Sherman SI; Duvic M
J Clin Endocrinol Metab; 2006 Jun; 91(6):2205-8. PubMed ID: 16595600
[TBL] [Abstract][Full Text] [Related]
20. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.
Wang Z; Ma J; Zhang H; Ramakrishna R; Mintzlaff D; Mathes DW; Pomfret EA; Lucia MS; Gao D; Haverkos BM; Wang Z
FEBS Open Bio; 2023 Jul; 13(7):1309-1319. PubMed ID: 37157185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
